1. Figure 1 A flow chart describing the systematic process followed for article selection. 
From: A systematic review of cost-effectiveness of percutaneous coronary intervention vs. surgery for the treatment of multivessel coronary artery disease in the drug-eluting stent era
Eur Heart J Qual Care Clin Outcomes. 2016;2(4): doi: /ehjqcco/qcw007
Eur Heart J Qual Care Clin Outcomes | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please

2. Figure 2 The incremental cost-effectiveness per QALY gained for CABG reported by nine economic evaluations (2014 USD). ASCERT, American College of Cardiology Foundation – The Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategies; CABG, coronary artery bypass surgery; FREEDOM, The Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease; PCI, percutaneous coronary intervention; QALY, quality-adjusted life years gained; SYNTAX, Synergy between PCI with Taxus and Cardiac Surgery; yrs, year/s.
From: A systematic review of cost-effectiveness of percutaneous coronary intervention vs. surgery for the treatment of multivessel coronary artery disease in the drug-eluting stent era
Eur Heart J Qual Care Clin Outcomes. 2016;2(4): doi: /ehjqcco/qcw007
Eur Heart J Qual Care Clin Outcomes | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please

3. Figure 3 The incremental cost-effectiveness per LYG gained for CABG reported by included economic evaluations (2014 USD). ASCERT, American College of Cardiology Foundation–The Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategies; CABG, coronary artery bypass surgery; LYG, life years gained; PCI, percutaneous coronary intervention; SYNTAX, Synergy between PCI with Taxus and Cardiac Surgery; yrs, year/s.
From: A systematic review of cost-effectiveness of percutaneous coronary intervention vs. surgery for the treatment of multivessel coronary artery disease in the drug-eluting stent era
Eur Heart J Qual Care Clin Outcomes. 2016;2(4): doi: /ehjqcco/qcw007
Eur Heart J Qual Care Clin Outcomes | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please

4. Figure 4 The incremental cost-effectiveness per MACCE avoided for CABG reported by included economic evaluations (2014 USD). CABG, coronary artery bypass surgery; MACCE, major adverse cardiac and cerebrovascular events; PCI, percutaneous coronary intervention; yrs, year/s.
From: A systematic review of cost-effectiveness of percutaneous coronary intervention vs. surgery for the treatment of multivessel coronary artery disease in the drug-eluting stent era
Eur Heart J Qual Care Clin Outcomes. 2016;2(4): doi: /ehjqcco/qcw007
Eur Heart J Qual Care Clin Outcomes | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please